LGM
AVBP icon

Logos Global Management’s ArriVent BioPharma AVBP Stock Holding History

Logos Global Management’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.07M Buy
+350,000
New +$7.9M 0.4% 51

Other funds holding AVBP

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Logos Global Management's AVBP Position: Q1 2026 in Review

Logos Global Management opened a new position in ArriVent BioPharma (AVBP) in Q1 2026: 350,000 shares worth $8.07M. The stake represents 0.4% of the portfolio and ranks #51 among its holdings.

139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • Logos Global Management held 350,000 shares of ArriVent BioPharma worth $8.07M as of Q1 2026.
  • ArriVent BioPharma was a new Logos Global Management position in Q1 2026.
  • ArriVent BioPharma made up 0.4% of Logos Global Management's portfolio in Q1 2026, its #51 holding.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on Logos Global Management's 13F filing for Q1 2026, filed 15 May 2026.